Evidence map›Paper›PMID 20078217›Full record

ReviewAnnual review of pathology2010

The senescence-associated secretory phenotype: the dark side of tumor suppression.

Jean-Philippe Coppé, Pierre-Yves Desprez, Ana Krtolica, Judith Campisi

Registry-linked trialAbstract readReview
In one paragraph

Review in Annual review of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04736251 (A Prospective Intra-patient Single-blinded Randomised Trial to Examine the Mechanistic Basis of fractiOnal Ablative carbOn Dioxide Laser Therapy in Treating Adult Burns and/or Trauma Patients With Hypertrophic Scarring), which is not on this map. Cited by 3,176 papers.

0numbers the graph read from it
0cells of the map it votes in
3,176citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04736251 unknown statusnot on this mapstarted 2019, after this paper: background citation

A Prospective Intra-patient Single-blinded Randomised Trial to Examine the Mechanistic Basis of fractiOnal Ablative carbOn Dioxide Laser Therapy in Treating Adult Burns and/or Trauma Patients With Hypertrophic Scarring

TypeobservationalSponsorNaiem MoiemenRan2019 to 2023Enrolled60ConditionsBurn Scar, Scar
3 · Its place in the literature

Who cites it

3,176 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Cytotoxic activity of selinexor in BRAFActa neuropathologica communications · 2026
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

3,116 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jean-Philippe CoppéLife Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA.
Pierre-Yves Desprez
Ana Krtolica
Judith Campisi

Funding

THE IMPACT OF CELLULAR DEFENSE ON THE ROLE OF Ku80 IN GENOME MAINTENANCE AND LONGP01AG017242 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI VIJG, JAN · 1999 to 2023
$46.1M
Systems Biology and Bioinformatics CoreP01AG041122 · NIA · MAYO CLINIC ROCHESTER · PI CAMPISI, JUDITH · 2012 to 2016
$9.8M
CELLULAR SENESCENCE AND CONTROL OF GENE EXPRESSIONR37AG009909 · NIA · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI CAMPISI, JUDITH · 1995 to 2015
$7.6M
NIA NIH HHS P01 AG017242NIA NIH HHS P01 AG041122NIA NIH HHS R37 AG009909
6 · The paper itself

Abstract

Cellular senescence is a tumor-suppressive mechanism that permanently arrests cells at risk for malignant transformation. However, accumulating evidence shows that senescent cells can have deleterious effects on the tissue microenvironment. The most significant of these effects is the acquisition of a senescence-associated secretory phenotype (SASP) that turns senescent fibroblasts into proinflammatory cells that have the ability to promote tumor progression.

Indexed as

Cellular SenescencePhenotypeCell Transformation, NeoplasticFibroblastsHumansNeoplasmsTumor Suppressor ProteinsTumor Suppressor Proteins

Identifiers

PMID20078217
PMCPMC4166495

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.